<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Denovicon Therapeutics</title>
	<atom:link href="https://www.denovicontx.com/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.denovicontx.com/</link>
	<description>BioTech Company</description>
	<lastBuildDate>Fri, 17 Apr 2026 00:07:08 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>

<image>
	<url>https://www.denovicontx.com/wp-content/uploads/2019/06/denovidon-graphic-150x150.jpg</url>
	<title>Denovicon Therapeutics</title>
	<link>https://www.denovicontx.com/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Denovicon Selected for DOE National Lab Collaboration on Quantum–Photonic Drug Discovery</title>
		<link>https://www.denovicontx.com/denovicon-selected-for-doe-national-lab-collaboration-on-quantum-photonic-drug-discovery/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Thu, 16 Apr 2026 23:32:23 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=2837</guid>

					<description><![CDATA[<p>FOR IMMEDIATE RELEASE San Diego, CA – April 16, 2026 – Denovicon Therapeutics has been competitively selected for an 18-month collaboration with the U.S. Department of Energy&#8217;s Center for Integrated Nanotechnologies (CINT) to validate photonic Ising machines for molecular optimization in drug discovery. The collaboration will benchmark Denovicon&#8217;s quantum physics-driven generative AI platform against photonic [&#8230;]</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-selected-for-doe-national-lab-collaboration-on-quantum-photonic-drug-discovery/">Denovicon Selected for DOE National Lab Collaboration on Quantum–Photonic Drug Discovery</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<style>
@media (max-width: 768px) {
  article h2 {
    font-size: 20px !important;
    line-height: 1.3 !important;
  }
  article table {
    display: block !important;
    overflow-x: auto !important;
    -webkit-overflow-scrolling: touch;
    font-size: 13px !important;
  }
}
</style>



<p><em>FOR IMMEDIATE RELEASE</em></p>



<p><strong>San Diego, CA – April 16, 2026</strong> – Denovicon Therapeutics has been competitively selected for an 18-month collaboration with the U.S. Department of Energy&#8217;s Center for Integrated Nanotechnologies (CINT) to validate photonic Ising machines for molecular optimization in drug discovery.</p>



<p>The collaboration will benchmark Denovicon&#8217;s quantum physics-driven generative AI platform against photonic hardware at CINT&#8217;s facilities at Sandia National Laboratories and Los Alamos National Laboratory. The project focuses on demonstrating how specialized photonic computing hardware can accelerate multi-objective optimization to design new small-molecule drugs.</p>



<p>&#8220;<em>The fundamental problem of drug discovery is to design molecules that meet the many necessary properties required of a drug molecule. Traditional computing approaches face fundamental limitations when designing new molecules across trillion-molecule spaces to meet these multiple constraints simultaneously,&#8221; said Scott Bembenek, PhD, Founder and CEO of Denovicon Therapeutics. &#8220;Photonic Ising machines offer a potential path to solve this problem, which would transform how we discover new small-molecule drugs. While several groups have looked into quantum computing in drug discovery, this collaboration will be, to our knowledge, the first to validate an end-to-end workflow combining drug discovery, multi-objective optimization, and photonic Ising hardware, which could establish a new paradigm for molecular design.</em>&#8220;</p>



<p>Denovicon&#8217;s quantum physics-driven generative AI platform enables direct deployment to emerging quantum hardware like the photonic machines at CINT. The CINT collaboration will provide experimental validation of photonic approaches for pharmaceutical applications.</p>



<h2 class="wp-block-heading">About Denovicon Therapeutics</h2>



<p>Denovicon Therapeutics is developing quantum-inspired AI platforms for small molecule drug discovery, with lead programs in DNA damage response and immuno-oncology. The company is based in La Jolla, California.</p>



<h2 class="wp-block-heading">About CINT</h2>



<p>CINT is a DOE Office of Science user facility jointly operated by Sandia National Laboratories and Los Alamos National Laboratory. Access to CINT resources is awarded through competitive peer review.</p>



<p>For partnership inquiries:</p>



<p>Zoey Pan<br>Head of Strategy &amp; External Collaborations<br>zoey@denovicontx.com</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-selected-for-doe-national-lab-collaboration-on-quantum-photonic-drug-discovery/">Denovicon Selected for DOE National Lab Collaboration on Quantum–Photonic Drug Discovery</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Denovicon Reports Discovery of DNT-1569: A Highly Potent and Selective Small-Molecule PARP7 Inhibitor for Immuno-Oncology</title>
		<link>https://www.denovicontx.com/denovicon-reports-discovery-of-dnt-1569-a-highly-selective-small-molecule-parp7-inhibitor-for-immuno-oncology/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Wed, 04 Mar 2026 02:22:47 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=2786</guid>

					<description><![CDATA[<p>A small molecule oral immunomodulator with first-in-class selectivity over PARP1 and PARP2 — computationally designed in less than a year San Diego, CA – March 4, 2026 – Denovicon Therapeutics today announces the discovery of DNT-1569, a small-molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) designed as a potential oral immunomodulatory therapy for solid tumors. To the [&#8230;]</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-reports-discovery-of-dnt-1569-a-highly-selective-small-molecule-parp7-inhibitor-for-immuno-oncology/">Denovicon Reports Discovery of DNT-1569: A Highly Potent and Selective Small-Molecule PARP7 Inhibitor for Immuno-Oncology</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<style>
@media (max-width: 768px) {
  article h2 {
    font-size: 20px !important;
    line-height: 1.3 !important;
  }
  article table {
    display: block !important;
    overflow-x: auto !important;
    -webkit-overflow-scrolling: touch;
    font-size: 13px !important;
  }
}
</style>



<p><em>A small molecule oral immunomodulator with first-in-class selectivity over PARP1 and PARP2 — computationally designed in less than a year</em></p>



<p><strong>San Diego, CA – March 4, 2026</strong> – Denovicon Therapeutics today announces the discovery of DNT-1569, a small-molecule inhibitor of poly(ADP-ribose) polymerase 7 (PARP7) designed as a potential oral immunomodulatory therapy for solid tumors. To the best of our knowledge, no small-molecule immuno-oncology drug has reached the market — the entire immunotherapy revolution to date relies on biologics. DNT-1569 is designed to change that. The compound demonstrates potent PARP7 inhibition with approximately 2,000-fold selectivity over PARP1 and 2,500-fold selectivity over PARP2 — a selectivity profile that distinguishes it from all known PARP7 inhibitors, including the clinical compound RBN-2397 (atamparib).</p>



<h2 class="wp-block-heading">Why PARP7 — and Why Selectivity Matters</h2>



<p>After nearly 25 years in drug discovery — including 17 years at Johnson &amp; Johnson, where I co-led seven clinical candidates — one pattern stands out: good mechanisms fail when the molecules carrying them aren&#8217;t clean enough to dose properly.</p>



<p>PARP7 is a compelling immuno-oncology target. Inhibiting PARP7 restores type I interferon signaling in tumor cells, activating the innate immune system and potentially converting immunologically &#8220;cold&#8221; tumors — the ones that don&#8217;t respond to checkpoint inhibitors like Keytruda — into &#8220;hot&#8221; tumors that the immune system can recognize and attack. PARP7 is dysregulated across multiple solid tumor types, including lung, breast, ovarian, head and neck, pancreatic, and colorectal cancers.</p>



<p>The clinical precedent exists. Ribon Therapeutics&#8217; RBN-2397 entered Phase 1 trials and demonstrated preliminary antitumor activity, establishing proof of concept that PARP7 inhibition produces clinical benefit. But RBN-2397 is not a selective PARP7 inhibitor — it potently inhibits PARP1 and PARP2 as well, which creates the same hematological toxicities seen with traditional PARP inhibitors. This likely resulted in tox-limited dosing and, consequently, the achievable efficacy.</p>



<p><strong><em>The mechanism is validated. The selectivity problem was not.</em></strong></p>



<h2 class="wp-block-heading">DNT-1569: Solving the Selectivity Problem</h2>



<p>DNT-1569 was designed to be the PARP7 inhibitor that RBN-2397 was not — one that inhibits the intended target without carrying off-target PARP1/2 liabilities.</p>



<p><strong>Biochemical Profile:</strong></p>



<table style="width:100%; border-collapse:collapse; font-family:inherit; font-size:inherit;">
<thead>
<tr style="background-color:#1B4F72;">
<th style="padding:12px 16px; text-align:left; color:#ffffff; border:1px solid #ddd;"></th>
<th style="padding:12px 16px; text-align:center; color:#ffffff; border:1px solid #ddd;">DNT-1569 (Denovicon)</th>
<th style="padding:12px 16px; text-align:center; color:#ffffff; border:1px solid #ddd;">RBN-2397 (Ribon)</th>
</tr>
</thead>
<tbody>
<tr style="background-color:#EBF5FB;">
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>PARP7</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">4 nM</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">3 nM</td>
</tr>
<tr>
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>PARP1</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">8,000 nM</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">37 nM</td>
</tr>
<tr style="background-color:#EBF5FB;">
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>PARP2</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">10,000 nM</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">17 nM</td>
</tr>
<tr>
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>PARP1 Selectivity</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">~2,000×</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">~12×</td>
</tr>
<tr style="background-color:#EBF5FB;">
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>PARP2 Selectivity</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">~2,500×</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">~6×</td>
</tr>
<tr>
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>Scaffold Novelty</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">Tanimoto = 0.14 vs. RBN-2397</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">—</td>
</tr>
<tr style="background-color:#EBF5FB;">
<td style="padding:10px 16px; border:1px solid #ddd;"><strong>Virtual Design Time</strong></td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">&lt; 2 days</td>
<td style="padding:10px 16px; text-align:center; border:1px solid #ddd;">Years (traditional)</td>
</tr>
</tbody>
</table>



<p>DNT-1569 matches RBN-2397&#8217;s PARP7 potency while pushing PARP1 and PARP2 activity into the micromolar range. This selectivity profile is designed to enable full therapeutic dosing of PARP7 without the PARP1/2-driven toxicities that likely constrained RBN-2397&#8217;s clinical performance.</p>



<p>Importantly, DNT-1569 sits on a novel chemical scaffold — a Tanimoto similarity of 0.14 relative to RBN-2397 confirms that this is not an analogue or derivative of existing PARP7 chemistry. The compound emerged from an entirely different design process, not from iterating on a known scaffold.</p>



<h2 class="wp-block-heading">How We Got Here</h2>



<p>DNT-1569 was designed using Denovicon&#8217;s computational drug discovery platform, which uses physics-based machine learning to design molecules with druglike properties built in from the start — not optimized after the fact.</p>



<p>Rather than starting with target affinity and then spending years trying to engineer in druglike properties — the traditional break-fix cycle that accounts for the majority of preclinical program failures — our approach optimizes across ADMET, pharmacokinetic, toxicity, and affinity properties from the outset. Every design decision maps to real chemical features that medicinal chemists can interrogate — no black boxes.</p>



<p><strong>The entire virtual design phase for DNT-1569 was completed in under two days. The program from inception to the selectivity data reported here took under one year.</strong></p>



<p>Since the DNT-1569 program, Denovicon&#8217;s platform has evolved into a quantum physics-driven generative AI architecture that extends these capabilities to trillion-molecule chemical spaces, enabling simultaneous multi-objective optimization in a single computational step. The core principle remains the same: build druglikeness in by design. The scale and speed at which we can now do it has fundamentally changed.</p>



<h2 class="wp-block-heading">Clinical Implications</h2>



<p>The immuno-oncology landscape is dominated by biologics — checkpoint inhibitors, CAR-T therapies, bispecific antibodies — all of which require infusion, cold chain logistics, specialized administration, and carry substantial cost. To the best of our knowledge, there is no marketed small molecule immuno-oncology drug. DNT-1569 is designed to address that gap: an oral small molecule that modulates the immune system&#8217;s ability to recognize and attack tumors.</p>



<p>A truly selective small molecule PARP7 inhibitor opens two therapeutic paths.</p>



<p><strong>Monotherapy: </strong>If PARP7 inhibition alone is sufficient to drive antitumor immunity in selected patient populations — as early evidence in squamous cell lung cancer and head and neck cancers suggests — a selective oral PARP7 inhibitor could offer meaningful clinical benefit without the toxicity burden of pan-PARP inhibition. As a small molecule, it reaches compartments that antibodies cannot — including the central nervous system — and can be manufactured and distributed at a fraction of the cost of biologics.</p>



<p><strong>Combination therapy: </strong>The greater opportunity may lie in combining a selective PARP7 inhibitor with existing immune checkpoint inhibitors. Approximately 70% of cancer patients do not respond to checkpoint inhibitors alone, largely because their tumors are immunologically cold. A selective PARP7 inhibitor that activates the type I interferon pathway — turning cold tumors hot — could serve as an oral immunomodulatory backbone for checkpoint inhibitor combinations. Critically, this combination is viable only if the PARP7 inhibitor does not add significant toxicity to the regimen. DNT-1569&#8217;s selectivity profile is designed to make that combination feasible.</p>



<p>An oral, well-tolerated small molecule immunomodulator would represent a new therapeutic modality — one with implications not just for efficacy, but for global patient access.</p>



<h2 class="wp-block-heading">What Comes Next</h2>



<p>Immune biomarker assays for DNT-1569 are underway. These data will provide the first readout on whether the selectivity advantage observed in biochemical assays translates to the expected immunomodulatory activity in cellular systems. Denovicon is actively engaging pharmaceutical partners for proof-of-concept collaborations around the PARP7 program and the broader quantum physics-driven generative AI platform.</p>



<h2 class="wp-block-heading">About Denovicon Therapeutics</h2>



<p>Denovicon Therapeutics, Inc. is a computational drug discovery company based in San Diego, California. Founded in 2019 by Scott Bembenek, PhD. Denovicon&#8217;s physics-based optimization platform generates lead-quality small molecule candidates with improved druglike properties across trillion-molecule chemical spaces. The company is a portfolio member of the Dassault Systèmes 3DEXPERIENCE Lab and a member of the ARPA-H Investor Catalyst Hub Spoke Network. Denovicon&#8217;s scientific advisory board includes drug discovery experts from both industry and academia. </p>



<p>For partnership inquiries:</p>



<p>Zoey Pan<br>Head of Strategy &amp; External Collaborations<br>zoey@denovicontx.com</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-reports-discovery-of-dnt-1569-a-highly-selective-small-molecule-parp7-inhibitor-for-immuno-oncology/">Denovicon Reports Discovery of DNT-1569: A Highly Potent and Selective Small-Molecule PARP7 Inhibitor for Immuno-Oncology</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs</title>
		<link>https://www.denovicontx.com/denovicon-introduces-ml-physics-driven-multi-objective-optimization-platform-for-small-molecule-drug-discovery/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Fri, 30 Jan 2026 01:24:32 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=2451</guid>

					<description><![CDATA[<p>After nearly 25 years in drug discovery, I’ve watched the same pattern repeat. Programs identify modest hits, then spend five to seven years attempting to optimize toward a clinical candidate</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-introduces-ml-physics-driven-multi-objective-optimization-platform-for-small-molecule-drug-discovery/">Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<style>
@media (max-width: 768px) {
  article h2 {
    font-size: 20px !important;
    line-height: 1.3 !important;
  }
}
</style>



<p><em>A druglikeness-first approach that searches trillion-molecule spaces to deliver lead-ready compounds</em></p>



<h2 class="wp-block-heading">The Drug Discovery Bottleneck</h2>



<p>After nearly 25 years in drug discovery, I&#8217;ve watched the same pattern repeat. Programs identify modest hits, then spend five to seven years attempting to optimize toward a clinical candidate—most of which never materialize. The failures are rarely due to target affinity. Instead, they stem from ADME, PK, toxicity, and developability issues that surface late, when the cost of failure is highest.</p>



<p>Yet modern drug discovery—both experimental and computational—remains overwhelmingly affinity-first.</p>



<p>Computationally, this constraint no longer applies.</p>



<p>So, we inverted the problem.</p>



<h2 class="wp-block-heading">Druglikeness First, Not as a Filter</h2>



<p>Denovicon&#8217;s quantum physics-driven generative AI for multi-objective optimization (MOO) of small-molecule drugs searches trillion-molecule, chemically diverse spaces for molecules that are drug-like from the outset, optimized simultaneously across multiple developability-relevant properties before target matching.</p>



<p>This is not a sequential workflow and not a post-hoc filtering step.</p>



<p>Instead, drug-relevant constraints are embedded directly into the optimization process, enabling the platform to identify molecules that satisfy competing requirements in a single, unified search.</p>



<p>The result is lead-quality molecules, not modest hits—and chemistry that medicinal teams can interrogate and advance with confidence.</p>



<h2 class="wp-block-heading">Interpretable Chemistry at Scale</h2>



<p>Unlike many generative approaches that rely on opaque latent representations, Denovicon&#8217;s platform is designed to produce outputs that support chemical interpretability and rational follow-up, enabling clear structure–property and structure–activity reasoning during optimization.</p>



<p>This allows discovery teams to understand why a molecule works, not just that it works—reducing downstream risk and accelerating decision-making.</p>



<h2 class="wp-block-heading">Improved Synthesizability by Design</h2>



<p>One of the most common limitations of generative AI in drug discovery is that computationally attractive molecules are often synthetically impractical. Many platforms treat synthesizability as a downstream filter—generate candidates first, then discard what can&#8217;t be made. By that point, much of the useful chemical space has been filtered away.</p>



<p>Denovicon&#8217;s platform optimizes for improved synthesizability as part of the multi-objective optimization itself—alongside the rest of the desired properties. The result is molecules that are not only predicted to have favorable drug properties but are also accessible through established chemistries.</p>



<h2 class="wp-block-heading">Customized to Your Program</h2>



<p>No two drug discovery programs share the same constraints. Teams bring existing chemical libraries, established SAR, and years of institutional knowledge.</p>



<p>Denovicon&#8217;s platform is customizable to leverage all these aspects. The optimization operates within real-world program constraints rather than generating molecules in a vacuum to ensure actionable items within an existing discovery program.</p>



<h2 class="wp-block-heading">Validated in a Real Drug Discovery Program</h2>



<p>Denovicon&#8217;s approach has already been validated in practice. Using its AI- and physics-based platform, Denovicon delivered a PARP7 inhibitor with greater than 2,000× selectivity over both PARP1 and PARP2 — compared to the pan-PARP clinical compound RBN-2397 (PARP7/PARP1/PARP2 = 3 nM/37 nM/17 nM).</p>



<p>The new multi-objective optimization platform builds on this proven foundation, extending its ability to search larger chemical spaces while optimizing across all key drug-relevant properties simultaneously.</p>



<h2 class="wp-block-heading">Built for Scale, Ready for the Future</h2>



<p>The platform is production-ready today, while architected for future compatibility with emerging computational hardware—allowing Denovicon to take advantage of new acceleration technologies as they mature, without changing the underlying discovery workflow.</p>



<h2 class="wp-block-heading">About Denovicon Therapeutics</h2>



<p>Denovicon Therapeutics is a biotechnology company developing AI- and physics-based computational platforms to transform small-molecule drug discovery by delivering lead-ready compounds through scalable, interpretable multi-objective optimization.</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-introduces-ml-physics-driven-multi-objective-optimization-platform-for-small-molecule-drug-discovery/">Denovicon Introduces Quantum Physics-Driven Generative AI For Multi-Objective Optimization of Small-Molecule Drugs</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator</title>
		<link>https://www.denovicontx.com/denovicon-renewed-for-the-3dexperience-lab-accelerator/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Fri, 28 Nov 2025 14:00:42 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=2651</guid>

					<description><![CDATA[<p>Denovicon Therapeutics has been renewed for a three-year membership in the 3DEXPERIENCE Lab accelerator, the global innovation program of Dassault Systèmes. Denovicon remains the only biotechnology company in the accelerator&#8217;s portfolio, underscoring the program&#8217;s confidence in our AI-driven approach to small-molecule drug discovery. Since our initial acceptance in October 2024, we have deepened our collaboration [&#8230;]</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-renewed-for-the-3dexperience-lab-accelerator/">Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Denovicon Therapeutics has been renewed for a three-year membership in the <a href="https://3dexperiencelab.3ds.com/en/projects/life/denovicon-therapeutics/">3DEXPERIENCE Lab accelerator</a>, the global innovation program of <a href="https://www.3ds.com/">Dassault Systèmes</a>. Denovicon remains the only biotechnology company in the accelerator&#8217;s portfolio, underscoring the program&#8217;s confidence in our AI-driven approach to small-molecule drug discovery.</p>



<p>Since our <a href="https://www.denovicontx.com/denovicon-is-accepted-into-the-3dexperience-lab-accelerator-2024/">initial acceptance in October 2024</a>, we have deepened our collaboration with Dassault Systèmes and its <a href="https://www.3ds.com/products/biovia">BIOVIA</a> life sciences division, working together across multiple projects at the intersection of computational chemistry and machine learning.</p>



<p>We look forward to continuing this work and to pushing the boundaries of what&#8217;s possible in AI-enabled drug discovery alongside the 3DEXPERIENCE Lab community.</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-renewed-for-the-3dexperience-lab-accelerator/">Denovicon Renewed for the 3DEXPERIENCE Lab Accelerator</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network</title>
		<link>https://www.denovicontx.com/denovicon-therapeutics-joins-arpa-h-investor-catalyst-hub-spoke-network/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Wed, 01 Oct 2025 20:47:14 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=2379</guid>

					<description><![CDATA[<p>San Diego, CA, October 1, 2025—Denovicon Therapeutics, an AI-driven drug discovery company based in San Diego, announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H). Based in the Greater Boston [&#8230;]</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-therapeutics-joins-arpa-h-investor-catalyst-hub-spoke-network/">Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>San Diego, CA, October 1, 2025—Denovicon Therapeutics, an AI-driven drug discovery company based in San Diego, announced today that it was selected as a spoke for the Investor Catalyst Hub, a regional hub of ARPANET-H, a nationwide health innovation network launched by the Advanced Research Projects Agency for Health (ARPA-H).</p>



<p>Based in the Greater Boston area and managed by VentureWell, the Investor Catalyst Hub seeks to accelerate the commercialization of groundbreaking and accessible biomedical solutions. It utilizes an innovative hub-and-spoke model designed to reach a wide range of organizations, with the ultimate aim of delivering scalable healthcare outcomes for all Americans.</p>



<p>Scott Bembenek, CEO and Founder of Denovicon, said:<br>“Becoming a Spoke member of the ARPA-H Investor Catalyst Hub marks an exciting milestone for Denovicon. It affirms our belief that bold science and cutting-edge technology can reshape drug discovery and reflects ARPA-H’s vision for accelerating breakthrough health solutions. Together with ARPA-H and this remarkable community, we are committed to shortening timelines, reducing costs, and bringing transformative therapies to patients faster than ever before.” </p>



<p><a href="https://www.denovicontx.com/wp-content/uploads/2025/10/ARPA-H-Investor-Catalyst-Hub-Spoke-Press-Release.pdf">Read Full Press Release</a></p>
<p>The post <a href="https://www.denovicontx.com/denovicon-therapeutics-joins-arpa-h-investor-catalyst-hub-spoke-network/">Denovicon Therapeutics Joins ARPA-H Investor Catalyst Hub Spoke Network</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Re-Inventing Drug Discovery</title>
		<link>https://www.denovicontx.com/re-inventing-drug-discovery/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Fri, 23 May 2025 20:47:53 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=2343</guid>

					<description><![CDATA[<p>Denovicon uses an innovative combination of machine learning and physics-based modeling to streamline the development of small molecule therapeutics, dramatically reducing R&#38;D timelines and improving clinical success. In a recent blog, Founder and CEO, Scott Bembenek reflects on the challenges of modern-day drug discovery and how Denovicon&#8217;s platform is leading the way in the computational/AI [&#8230;]</p>
<p>The post <a href="https://www.denovicontx.com/re-inventing-drug-discovery/">Re-Inventing Drug Discovery</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>Denovicon uses an innovative combination of machine learning and physics-based modeling to streamline the development of small molecule therapeutics, dramatically reducing R&amp;D timelines and improving clinical success. In a recent <a href="https://blog.3ds.com/brands/biovia/re-inventing-drug-discovery/">blog</a>, Founder and CEO, Scott Bembenek reflects on the challenges of modern-day drug discovery and how Denovicon&#8217;s platform is leading the way in the computational/AI drug discovery platform space. In its kickoff project on next-generation PARP1 inhibitors, the platform delivered an unprecedented 80% success rate, followed by a 59% success rate in their first-in-class PARP7 project (both used a high bar of 50% inhibition @ 1µM as the cutoff). Moreover, Bembenek reflects on Denovicon&#8217;s strategic collaboration with Biovia and parent company Dassault Systèmes and how the combination of a proprietary platform in combination with enterprise software really is the best of both worlds. </p>
<p>The post <a href="https://www.denovicontx.com/re-inventing-drug-discovery/">Re-Inventing Drug Discovery</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator</title>
		<link>https://www.denovicontx.com/denovicon-is-accepted-into-the-3dexperience-lab-accelerator-2024/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Thu, 24 Oct 2024 22:00:39 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=1822</guid>

					<description><![CDATA[<p>On October 21, 2024, Denovicon Therapeutics was officially accepted into the 3DEXPERIENCE Lab&#160;accelerator. &#8220;I am very pleased to welcome Denovicon Therapeutics to drive this [revolution in drug discovery] effort and bring something really disruptive in this domain,&#8221; said Frederic Vacher, Head of Innovation at Dassault Systèmes. Jason Benedict of BIOVIA also expressed his enthusiasm, &#8220;We’ve [&#8230;]</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-is-accepted-into-the-3dexperience-lab-accelerator-2024/">Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>On October 21, 2024, Denovicon Therapeutics <a href="https://www.linkedin.com/posts/3dexperiencelab_if-we-create-an-aiml-generative-design-activity-7254099151947198465-6fEr?utm_source=share&amp;utm_medium=member_desktop">was officially accepted into the</a><a style="font-size: revert;" href="https://www.linkedin.com/posts/3dexperiencelab_if-we-create-an-aiml-generative-design-activity-7254099151947198465-6fEr?utm_source=share&amp;utm_medium=member_desktop"> 3DEXPERIENCE Lab&nbsp;accelerator</a><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);">. &#8220;I am very pleased to welcome Denovicon Therapeutics to drive this [revolution in drug discovery] effort and bring something really disruptive in this domain,&#8221; </span><a href="https://www.linkedin.com/posts/fredericvacher_ifwe-drug-therapeutics-activity-7255178772205776896-q41k?utm_source=share&amp;utm_medium=member_desktop">said Frederic Vacher</a><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);">, Head of Innovation at <a href="https://www.linkedin.com/company/dassaultsystemes/posts/?feedView=all">Dassault Systèmes</a>. </span><a href="https://www.linkedin.com/posts/3dexperiencelab_if-we-create-an-aiml-generative-design-activity-7254099151947198465-6fEr?utm_source=share&amp;utm_medium=member_desktop"></a><a style="font-size: revert; background-color: rgb(255, 255, 255);" href="https://www.linkedin.com/in/jabenedict/">Jason Benedict</a><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);"> of </span><a href="https://www.linkedin.com/posts/3dexperiencelab_if-we-create-an-aiml-generative-design-activity-7254099151947198465-6fEr?utm_source=share&amp;utm_medium=member_desktop"></a><a style="font-size: revert; background-color: rgb(255, 255, 255);" href="https://www.linkedin.com/company/biovia/posts/?feedView=all">BIOVIA</a><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);"> </span><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);">also <a href="https://www.linkedin.com/posts/jabenedict_if-we-create-an-aiml-generative-design-activity-7254291840902799361-RzUY?utm_source=share&amp;utm_medium=member_desktop">expressed his enthusiasm</a>, &#8220;We’ve worked with [Denovicon] for some time on many topics. I&#8217;m excited for this collaboration through our </span><a href="https://www.linkedin.com/company/3dexperiencelab/posts/?feedView=all">3DEXPERIENCE Lab</a><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);"> and look forward to seeing Denovicon Therapeutics breakthrough discoveries.&#8221; You can learn more about the Denovicon–3DEXPERIENCE Lab collaboration </span><a href="https://3dexperiencelab.3ds.com/en/projects/life/denovicon-therapeutics/">here</a><span style="font-size: revert; background-color: rgb(255, 255, 255); color: rgb(102, 102, 102);">. </span></p>
<p>The post <a href="https://www.denovicontx.com/denovicon-is-accepted-into-the-3dexperience-lab-accelerator-2024/">Denovicon is Accepted into the 3DEXPERIENCE Lab Accelerator</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>DRUG DISCOVERY CHEMISTRY CONFERENCE 2023</title>
		<link>https://www.denovicontx.com/drug-discovery-chemistry-conference-2023/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Mon, 10 Apr 2023 21:50:51 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=1676</guid>

					<description><![CDATA[<p>On April 12, 2023, Denovicon Therapeutics Founder &#38; CEO, Scott Bembenek, will present on ‘Enhanced Active Learning by Combining Machine Learning and Structure-Based Methods’ at the Drug Discovery Chemistry Conference: Artificial Intelligence for Early Drug Discovery &#8211; Part 2  in San Diego, CA.</p>
<p>The post <a href="https://www.denovicontx.com/drug-discovery-chemistry-conference-2023/">DRUG DISCOVERY CHEMISTRY CONFERENCE 2023</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>On April 12, 2023, Denovicon Therapeutics Founder &amp; CEO, Scott Bembenek, will present on ‘Enhanced Active Learning by Combining Machine Learning and Structure-Based Methods’ at the <a href="https://www.drugdiscoverychemistry.com/artificial-intelligence-part2">Drug Discovery Chemistry Conference: Artificial Intelligence for Early Drug Discovery &#8211; Part 2</a>  in San Diego, CA.</p>
<p>The post <a href="https://www.denovicontx.com/drug-discovery-chemistry-conference-2023/">DRUG DISCOVERY CHEMISTRY CONFERENCE 2023</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Biovia User Group Meeting 2022</title>
		<link>https://www.denovicontx.com/biovia-user-group-meeting-2022/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Tue, 18 Oct 2022 20:34:23 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=1646</guid>

					<description><![CDATA[<p>On October 11, 2022, Denovicon Therapeutics Founder &#38; CEO, Scott Bembenek, presented on &#8216;An AI–Molecular Modeling Platform for Streamlining Small-Molecule Drug Discovery&#8217; at the Biovia User Group Meeting 2022.</p>
<p>The post <a href="https://www.denovicontx.com/biovia-user-group-meeting-2022/">Biovia User Group Meeting 2022</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>On October 11, 2022, Denovicon Therapeutics Founder &amp; CEO, Scott Bembenek, presented on &#8216;An AI–Molecular Modeling Platform for Streamlining Small-Molecule Drug Discovery&#8217; at the <a href="https://events.3ds.com/biovia-conference-2022">Biovia User Group Meeting 2022.</a></p>
<p>The post <a href="https://www.denovicontx.com/biovia-user-group-meeting-2022/">Biovia User Group Meeting 2022</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Denovicon Founder to Present at SLAS 2022</title>
		<link>https://www.denovicontx.com/denovicon-founder-to-present-at-slas-2022/</link>
		
		<dc:creator><![CDATA[SBadmin]]></dc:creator>
		<pubDate>Fri, 04 Feb 2022 01:39:01 +0000</pubDate>
				<category><![CDATA[News]]></category>
		<guid isPermaLink="false">https://www.denovicontx.com/?p=1618</guid>

					<description><![CDATA[<p>On February 8, 2022, Denovicon Therapeutics Founder &#38; CEO, Scott Bembenek talked (along with BIOVIA&#8217;s Guy Oshiro) at SLAS 2022 about how AI and the use of virtual–real cycles is revolutionizing the drug discovery process.</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-founder-to-present-at-slas-2022/">Denovicon Founder to Present at SLAS 2022</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></description>
										<content:encoded><![CDATA[
<p>On February 8, 2022, Denovicon Therapeutics Founder &amp; CEO, Scott Bembenek talked (along with BIOVIA&#8217;s Guy Oshiro) at <a href="https://www.slas.org/events-calendar/slas2022-international-conference-and-exhibition/">SLAS 2022</a> about how AI and the use of virtual–real cycles is revolutionizing the drug discovery process.</p>
<p>The post <a href="https://www.denovicontx.com/denovicon-founder-to-present-at-slas-2022/">Denovicon Founder to Present at SLAS 2022</a> appeared first on <a href="https://www.denovicontx.com">Denovicon Therapeutics</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
